Fidele Ngabo1, Jacqueline E Tate2, Maurice Gatera3, Celse Rugambwa4, Philippe Donnen5, Philippe Lepage6, Jason M Mwenda7, Agnes Binagwaho8, Umesh D Parashar2. 1. Université Libre de Bruxelles, Ecole de Santé Publique, Centre de Recherche Politiques et Systèmes de Santé-Santé Internationale, Brussels, Belgium. Electronic address: ngabog@yahoo.fr. 2. Centers for Disease Control and Prevention, Atlanta, GA, USA. 3. Rwanda Biomedical Centre, Kigali, Rwanda. 4. World Health Organization, Rwanda Office, Kigali, Rwanda. 5. Université Libre de Bruxelles, Ecole de Santé Publique, Centre de Recherche Politiques et Systèmes de Santé-Santé Internationale, Brussels, Belgium. 6. Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Brussels, Belgium. 7. World Health Organization, African Regional Office, Brazzaville, Congo. 8. Ministry of Health, Kigali, Rwanda; Harvard Medical School, Boston, MA, USA; Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
Abstract
BACKGROUND: In May, 2012, Rwanda became the first low-income African country to introduce pentavalent rotavirus vaccine into its routine national immunisation programme. Although the potential health benefits of rotavirus vaccination are huge in low-income African countries that account for more than half the global deaths from rotavirus, concerns remain about the performance of oral rotavirus vaccines in these challenging settings. METHODS: We conducted a time-series analysis to examine trends in admissions to hospital for non-bloody diarrhoea in children younger than 5 years in Rwanda between Jan 1, 2009, and Dec 31, 2014, using monthly discharge data from the Health Management Information System. Additionally, we reviewed the registries in the paediatric wards at six hospitals from 2009 to 2014 and abstracted the number of total admissions and admissions for diarrhoea in children younger than 5 years by admission month and age group. We studied trends in admissions specific to rotavirus at one hospital that had undertaken active rotavirus surveillance from 2011 to 2014. We assessed changes in rotavirus epidemiology by use of data from eight active surveillance hospitals. FINDINGS: Compared with the 2009-11 prevaccine baseline, hospital admissions for non-bloody diarrhoea captured by the Health Management Information System fell by 17-29% from a pre-vaccine median of 4051 to 2881 in 2013 and 3371 in 2014, admissions for acute gastroenteritis captured in paediatric ward registries decreased by 48-49%, and admissions specific to rotavirus captured by active surveillance fell by 61-70%. The greatest effect was recorded in children age-eligible to be vaccinated, but we noted a decrease in the proportion of children with diarrhoea testing positive for rotavirus in almost every age group. INTERPRETATION: The number of admissions to hospital for diarrhoea and rotavirus in Rwanda fell substantially after rotavirus vaccine implementation, including among older children age-ineligible for vaccination, suggesting indirect protection through reduced transmission of rotavirus. These data highlight the benefits of routine vaccination against rotavirus in low-income settings. FUNDING: Gavi, the Vaccine Alliance and the Government of Rwanda.
BACKGROUND: In May, 2012, Rwanda became the first low-income African country to introduce pentavalent rotavirus vaccine into its routine national immunisation programme. Although the potential health benefits of rotavirus vaccination are huge in low-income African countries that account for more than half the global deaths from rotavirus, concerns remain about the performance of oral rotavirus vaccines in these challenging settings. METHODS: We conducted a time-series analysis to examine trends in admissions to hospital for non-bloody diarrhoea in children younger than 5 years in Rwanda between Jan 1, 2009, and Dec 31, 2014, using monthly discharge data from the Health Management Information System. Additionally, we reviewed the registries in the paediatric wards at six hospitals from 2009 to 2014 and abstracted the number of total admissions and admissions for diarrhoea in children younger than 5 years by admission month and age group. We studied trends in admissions specific to rotavirus at one hospital that had undertaken active rotavirus surveillance from 2011 to 2014. We assessed changes in rotavirus epidemiology by use of data from eight active surveillance hospitals. FINDINGS: Compared with the 2009-11 prevaccine baseline, hospital admissions for non-bloody diarrhoea captured by the Health Management Information System fell by 17-29% from a pre-vaccine median of 4051 to 2881 in 2013 and 3371 in 2014, admissions for acute gastroenteritis captured in paediatric ward registries decreased by 48-49%, and admissions specific to rotavirus captured by active surveillance fell by 61-70%. The greatest effect was recorded in children age-eligible to be vaccinated, but we noted a decrease in the proportion of children with diarrhoea testing positive for rotavirus in almost every age group. INTERPRETATION: The number of admissions to hospital for diarrhoea and rotavirus in Rwanda fell substantially after rotavirus vaccine implementation, including among older children age-ineligible for vaccination, suggesting indirect protection through reduced transmission of rotavirus. These data highlight the benefits of routine vaccination against rotavirus in low-income settings. FUNDING: Gavi, the Vaccine Alliance and the Government of Rwanda.
Authors: Virginia E Pitzer; Aisleen Bennett; Naor Bar-Zeev; Khuzwayo C Jere; Benjamin A Lopman; Joseph A Lewnard; Umesh D Parashar; Nigel A Cunliffe Journal: Sci Transl Med Date: 2019-08-14 Impact factor: 17.956
Authors: V L Rahajamanana; J L Raboba; A Rakotozanany; N J Razafindraibe; E J P R Andriatahirintsoa; A C Razafindrakoto; S A Mioramalala; C Razaiarimanga; G G Weldegebriel; E Burnett; J M Mwenda; M Seheri; M J Mphahlele; A L Robinson Journal: Vaccine Date: 2017-09-25 Impact factor: 3.641
Authors: Christabel C Enweronu-Laryea; George Armah; Kwamena W Sagoe; Daniel Ansong; Emmanuel Addo-Yobo; Stanley K Diamenu; Jason M Mwenda; Umesh D Parashar; Jacqueline E Tate Journal: Vaccine Date: 2018-05-08 Impact factor: 3.641
Authors: Minesh P Shah; Jacqueline E Tate; Jason M Mwenda; A Duncan Steele; Umesh D Parashar Journal: Expert Rev Vaccines Date: 2017-09-04 Impact factor: 5.217
Authors: Amadou Diop; Aliou Thiongane; Jason M Mwenda; Negar Aliabadi; Mouhamadou A Sonko; Aliou Diallo; Babacar Ndoye; Papa M Faye; Idrissa D Ba; Umesh D Parashar; Jacqueline E Tate; Ousmane Ndiaye; Moussa F Cissé; Mamadou Ba Journal: Vaccine Date: 2017-11-20 Impact factor: 3.641